Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, Ransier A, Chenine AL, Asokan M, Bailer RT, Bose M, Cagigi A, Cale EM, Chuang GY, Darko S, Driscoll JI, Druz A, Gorman J, Laboune F, Louder MK, McKee K, Mendez L, Moody MA, O'Sullivan AM, Owen C, Peng D, Rawi R, Sanders-Buell E, Shen CH, Shiakolas AR, Stephens T, Tsybovsky Y, Tucker C, Verardi R, Wang K, Zhou J, Zhou T, Georgiou G, Alam SM, Haynes BF, Rolland M, Matyas GR, Polonis VR, McDermott AB, Douek DC, Shapiro L, Tovanabutra S, Michael NL, Mascola JR, Robb ML, Kwong PD, Doria-Rose NA.

Immunity. 2019 Mar 19;50(3):677-691.e13. doi: 10.1016/j.immuni.2019.02.008. Epub 2019 Mar 12.

PMID:
30876875
2.

A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.

Zhou T, Zheng A, Baxa U, Chuang GY, Georgiev IS, Kong R, O'Dell S, Shahzad-Ul-Hussan S, Shen CH, Tsybovsky Y, Bailer RT, Gift SK, Louder MK, McKee K, Rawi R, Stevenson CH, Stewart-Jones GBE, Taft JD, Waltari E, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CD, Wu CY; NISC Comparative Sequencing Program, Mullikin JC, Bewley CA, Burton DR, Polonis VR, Shapiro L, Wong CH, Mascola JR, Kwong PD, Wu X.

Immunity. 2018 Mar 20;48(3):500-513.e6. doi: 10.1016/j.immuni.2018.02.013. Epub 2018 Mar 13.

3.

Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.

Chenine AL, Merbah M, Wieczorek L, Molnar S, Mann B, Lee J, OʼSullivan AM, Bose M, Sanders-Buell E, Kijak GH, Herrera C, McLinden R, OʼConnell RJ, Michael NL, Robb ML, Kim JH, Polonis VR, Tovanabutra S.

J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):348-355. doi: 10.1097/QAI.0000000000001675.

4.

Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.

Emmer KL, Wieczorek L, Tuyishime S, Molnar S, Polonis VR, Ertl HC.

AIDS. 2016 Oct 23;30(16):2405-2414.

5.

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.

Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, Missanga M, Mann P, Wahren B, Ferrari G, Polonis VR, Robb ML, Weber J, Tatoud R, Maboko L, Hoelscher M, Lyamuya EF, Biberfeld G, Sandström E, Kroidl A, Bakari M, Nilsson C, McCormack S.

PLoS One. 2016 May 18;11(5):e0155702. doi: 10.1371/journal.pone.0155702. eCollection 2016.

6.

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

O'Connell RJ, Excler JL, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Liu M, Wieczorek L, McNeil JG, El-Habib R, Michael NL, Gilliam BL, Paris R, VanCott TC, Tomaras GD, Birx DL, Robb ML, Kim JH.

J Infect Dis. 2016 Jun 15;213(12):1946-54. doi: 10.1093/infdis/jiw059. Epub 2016 Feb 11.

7.

Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.

Beck Z, Matyas GR, Jalah R, Rao M, Polonis VR, Alving CR.

Vaccine. 2015 Oct 13;33(42):5578-5587. doi: 10.1016/j.vaccine.2015.09.001. Epub 2015 Sep 13.

PMID:
26372857
8.

Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Wieczorek L, Krebs SJ, Kalyanaraman V, Whitney S, Tovanabutra S, Moscoso CG, Sanders-Buell E, Williams C, Slike B, Molnar S, Dussupt V, Alam SM, Chenine AL, Tong T, Hill EL, Liao HX, Hoelscher M, Maboko L, Zolla-Pazner S, Haynes BF, Pensiero M, McCutchan F, Malek-Salehi S, Cheng RH, Robb ML, VanCott T, Michael NL, Marovich MA, Alving CR, Matyas GR, Rao M, Polonis VR.

J Virol. 2015 Aug;89(15):7478-93. doi: 10.1128/JVI.00412-15. Epub 2015 May 13.

9.

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.

Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, Marovich MA, Earl P, Moss B, Ochsenbauer C, Wahren B, Mhalu F, Sandström E, Biberfeld G, Ferrari G, Polonis VR.

PLoS One. 2015 Apr 14;10(4):e0118486. doi: 10.1371/journal.pone.0118486. eCollection 2015.

10.

High-throughput multiplex HLA genotyping by next-generation sequencing using multi-locus individual tagging.

Ehrenberg PK, Geretz A, Baldwin KM, Apps R, Polonis VR, Robb ML, Kim JH, Michael NL, Thomas R.

BMC Genomics. 2014 Oct 6;15:864. doi: 10.1186/1471-2164-15-864.

11.

Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Lakhashe SK, Byrareddy SN, Zhou M, Bachler BC, Hemashettar G, Hu SL, Villinger F, Else JG, Stock S, Lee SJ, Vargas-Inchaustegui DA, Cofano EB, Robert-Guroff M, Johnson WE, Polonis VR, Forthal DN, Loret EP, Rasmussen RA, Ruprecht RM.

Vaccine. 2014 Nov 12;32(48):6527-36. doi: 10.1016/j.vaccine.2014.08.065. Epub 2014 Sep 20.

12.

Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis VR, Levy JA, Szoka FC Jr.

Clin Vaccine Immunol. 2014 Aug;21(8):1086-93. doi: 10.1128/CVI.00320-14. Epub 2014 May 28.

13.

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.

Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal DN, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM.

Retrovirology. 2014 Jan 20;11:8. doi: 10.1186/1742-4690-11-8.

14.

Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.

McLinden RJ, Labranche CC, Chenine AL, Polonis VR, Eller MA, Wieczorek L, Ochsenbauer C, Kappes JC, Perfetto S, Montefiori DC, Michael NL, Kim JH.

PLoS One. 2013 Nov 28;8(11):e77756. doi: 10.1371/journal.pone.0077756. eCollection 2013.

15.

Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone.

Chenine AL, Wieczorek L, Sanders-Buell E, Wesberry M, Towle T, Pillis DM, Molnar S, McLinden R, Edmonds T, Hirsch I, O'Connell R, McCutchan FE, Montefiori DC, Ochsenbauer C, Kappes JC, Kim JH, Polonis VR, Tovanabutra S.

PLoS One. 2013 Nov 29;8(11):e76104. doi: 10.1371/journal.pone.0076104. eCollection 2013.

16.

Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling.

Wieczorek L, Brown BK, Delsarto Macedo C, Wesberry-Schmierer M, Ngauy V, Rosa Borges A, Michael NL, Marovich MA, Montefiori DC, Polonis VR.

Virology. 2013 Dec;447(1-2):240-8. doi: 10.1016/j.virol.2013.09.014. Epub 2013 Oct 5.

17.

Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.

Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS.

J Virol. 2014 Jan;88(2):1125-39. doi: 10.1128/JVI.02566-13. Epub 2013 Nov 6.

18.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

19.

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, Fong Y, Alam SM, Overman RG, Denny T, Ferrari G, Ochsenbauer C, Kappes JC, Polonis VR, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Montefiori DC, Gilbert P, Michael NL, Kim JH, Haynes BF, Tomaras GD.

J Virol. 2013 Jul;87(14):7828-36. doi: 10.1128/JVI.02737-12. Epub 2013 May 8.

20.

Designing a soluble near full-length HIV-1 gp41 trimer.

Gao G, Wieczorek L, Peachman KK, Polonis VR, Alving CR, Rao M, Rao VB.

J Biol Chem. 2013 Jan 4;288(1):234-46. doi: 10.1074/jbc.M112.424432. Epub 2012 Nov 26.

21.

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA.

PLoS One. 2012;7(9):e45840. doi: 10.1371/journal.pone.0045840. Epub 2012 Sep 26.

22.

Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.

Zhang MY, Yuan T, Li J, Rosa Borges A, Watkins JD, Guenaga J, Yang Z, Wang Y, Wilson R, Li Y, Polonis VR, Pincus SH, Ruprecht RM, Dimitrov DS.

PLoS One. 2012;7(9):e44241. doi: 10.1371/journal.pone.0044241. Epub 2012 Sep 10.

23.

Isolation of monoclonal antibodies with predetermined conformational epitope specificity.

Sholukh AM, Mukhtar MM, Humbert M, Essono SS, Watkins JD, Vyas HK, Shanmuganathan V, Hemashettar G, Kahn M, Hu SL, Montefiori DC, Polonis VR, Schur PH, Ruprecht RM.

PLoS One. 2012;7(6):e38943. doi: 10.1371/journal.pone.0038943. Epub 2012 Jun 21.

24.

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH.

J Infect Dis. 2012 Aug 1;206(3):431-41. doi: 10.1093/infdis/jis367. Epub 2012 May 25.

25.

The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization.

Brown BK, Wieczorek L, Kijak G, Lombardi K, Currier J, Wesberry M, Kappes JC, Ngauy V, Marovich M, Michael N, Ochsenbauer C, Montefiori DC, Polonis VR.

PLoS One. 2012;7(4):e29454. doi: 10.1371/journal.pone.0029454. Epub 2012 Apr 11.

26.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC.

Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9.

27.

HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.

Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, Gurunathan S, Francis D, Ratto-Kim S, Karnasuta C, de Souza MS, Polonis VR, Brown AE, Kim JH, Stephens HA; Thai AIDS Vaccine Evaluation Group.

Vaccine. 2012 Jan 20;30(5):832-6. doi: 10.1016/j.vaccine.2011.11.002. Epub 2011 Nov 12.

PMID:
22085554
28.

Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).

McLinden RJ, Paris RM, Polonis VR, Close NC, Su Z, Shikuma CM, Margolis DM, Kim JH.

AIDS. 2012 Jan 2;26(1):1-9. doi: 10.1097/QAD.0b013e32834d606e.

PMID:
21971356
29.

A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.

Eller MA, Slike BM, Cox JH, Lesho E, Wang Z, Currier JR, Darden JM, Polonis VR, Vahey MT, Peel S, Robb ML, Michael NL, Marovich MA.

PLoS One. 2011;6(9):e24254. doi: 10.1371/journal.pone.0024254. Epub 2011 Sep 16.

30.

B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.

Oballah P, Flach B, Eller LA, Eller MA, Ouma B, de Souza M, Kibuuka HN, Wabwire-Mangen F, Brown BK, Michael NL, Robb ML, Montefiori D, Polonis VR.

PLoS One. 2011;6(8):e22653. doi: 10.1371/journal.pone.0022653. Epub 2011 Aug 23.

31.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Bråve A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E.

Vaccine. 2011 Oct 26;29(46):8417-28. doi: 10.1016/j.vaccine.2011.08.001. Epub 2011 Aug 22.

32.

Infection of human peripheral blood mononuclear cells by erythrocyte-bound HIV-1: effects of antibodies and complement.

Beck Z, Brown BK, Matyas GR, Polonis VR, Rao M, Alving CR.

Virology. 2011 Apr 10;412(2):441-7. doi: 10.1016/j.virol.2011.01.037. Epub 2011 Feb 21.

33.

The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization.

Peachman KK, Wieczorek L, Matyas GR, Polonis VR, Alving CR, Rao M.

Viral Immunol. 2010 Dec;23(6):627-32. doi: 10.1089/vim.2010.0061.

PMID:
21142448
34.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

35.

Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Brown BK, Cox J, Gillis A, VanCott TC, Marovich M, Milazzo M, Antonille TS, Wieczorek L, McKee KT Jr, Metcalfe K, Mallory RM, Birx D, Polonis VR, Robb ML.

PLoS One. 2010 Nov 5;5(11):e13849. doi: 10.1371/journal.pone.0013849.

36.

The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies.

Peachman KK, Wieczorek L, Polonis VR, Alving CR, Rao M.

Virology. 2010 Dec 20;408(2):213-23. doi: 10.1016/j.virol.2010.09.029. Epub 2010 Oct 20.

37.

Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.

Rosa Borges A, Wieczorek L, Johnson B, Benesi AJ, Brown BK, Kensinger RD, Krebs FC, Wigdahl B, Blumenthal R, Puri A, McCutchan FE, Birx DL, Polonis VR, Schengrund CL.

Virology. 2010 Dec 5;408(1):80-8. doi: 10.1016/j.virol.2010.09.004. Epub 2010 Sep 28.

38.

Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.

Zhang MY, Borges AR, Ptak RG, Wang Y, Dimitrov AS, Alam SM, Wieczorek L, Bouma P, Fouts T, Jiang S, Polonis VR, Haynes BF, Quinnan GV, Montefiori DC, Dimitrov DS.

MAbs. 2010 May-Jun;2(3):266-74. Epub 2010 May 5.

39.

Impact of host cell variation on the neutralization of HIV-1 in vitro.

Polonis VR, Schuitemaker H, Bunnik EM, Brown BK, Scarlatti G.

Curr Opin HIV AIDS. 2009 Sep;4(5):400-7. doi: 10.1097/COH.0b013e32832edc50. Review.

PMID:
20048704
40.

Human erythrocytes selectively bind and enrich infectious HIV-1 virions.

Beck Z, Brown BK, Wieczorek L, Peachman KK, Matyas GR, Polonis VR, Rao M, Alving CR.

PLoS One. 2009 Dec 14;4(12):e8297. doi: 10.1371/journal.pone.0008297.

41.

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR.

J Virol. 2010 Feb;84(3):1439-52. doi: 10.1128/JVI.02108-09. Epub 2009 Nov 25.

42.

Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.

Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, Polonis VR, Alving CR.

AIDS. 2009 Oct 23;23(16):2069-77. doi: 10.1097/QAD.0b013e32832faea5.

PMID:
19710597
43.

Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype.

Nedellec R, Coetzer M, Shimizu N, Hoshino H, Polonis VR, Morris L, Mårtensson UE, Binley J, Overbaugh J, Mosier DE.

J Virol. 2009 Sep;83(17):8353-63. doi: 10.1128/JVI.00780-09. Epub 2009 Jun 24.

44.

Expression of Human CD4 and chemokine receptors in cotton rat cells confers permissiveness for productive HIV infection.

Blanco JC, Pletneva LM, Wieczorek L, Khetawat D, Stantchev TS, Broder CC, Polonis VR, Prince GA.

Virol J. 2009 May 14;6:57. doi: 10.1186/1743-422X-6-57.

45.

Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India.

Kulkarni SS, Lapedes A, Tang H, Gnanakaran S, Daniels MG, Zhang M, Bhattacharya T, Li M, Polonis VR, McCutchan FE, Morris L, Ellenberger D, Butera ST, Bollinger RC, Korber BT, Paranjape RS, Montefiori DC.

Virology. 2009 Mar 15;385(2):505-20. doi: 10.1016/j.virol.2008.12.032. Epub 2009 Jan 23.

46.

Serum levels of MIP-1beta and RANTES in HIV-1 subtype CRF01_AE infected patients with different rates of disease progression.

Chuenchitra T, Wasi C, de Souza M, Nitayaphan S, Louisirirotchanakul S, Sutthent R, Brown AE, Birx DL, Polonis VR.

Southeast Asian J Trop Med Public Health. 2008 Sep;39(5):856-62.

PMID:
19058580
47.

Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.

Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML, Birx DL, Michael NL, McCutchan FE, Polonis VR.

Virology. 2008 Jun 5;375(2):529-38. doi: 10.1016/j.virol.2008.02.022. Epub 2008 Apr 22.

48.

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.

Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyö EM, Montefiori DC, McCutchan FE, Michael NL.

Virology. 2008 Jun 5;375(2):315-20. doi: 10.1016/j.virol.2008.02.007. Epub 2008 Mar 25. Review.

49.

Host genetic analysis of HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression.

Louisirirotchanakul S, Sutthent R, Wasi C, Chuenchitra T, Nitayaphan S, Brown AE, Polonis VR, Nakayama EE, Shioda T, Liu H, Takebe Y.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1605-8. No abstract available.

PMID:
18160021
50.

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH; Thai AIDS Vaccine Evaluation Group.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55.

PMID:
17909315

Supplemental Content

Loading ...
Support Center